Navigation Links
Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance
Date:9/26/2007

HAIFA, Israel, Sept. 26 /PRNewswire/ -- Rcadia Medical Imaging, Ltd., developer of novel computer-aided diagnostic software, has received a second U.S. Federal Food and Drug Administration (FDA) clearance to market its COR Analyzer family of products, which assists in triaging patients for coronary artery disease (CAD). The new approval includes segmentation of the coronary tree with no human intervention and automatic detection of pathologies in the main coronary arteries.

Coronary artery disease is a major underlying cause for acute chest pain in Emergency Department (ED) patients. Annually, more than 5 million US patients present in the ED with acute chest pain. CT Angiography (CTA) is being rapidly adopted to triage patients in EDs across the U.S. Rcadia's COR Analyzer quickly identifies coronary artery disease and helps exclude patients without coronary arterial disease with a high negative predictive value (NPV). Rcadia's COR Analyzer system uses proprietary image processing algorithms allowing a no human intervention analysis of Coronary CTA studies to characterize patients. While improving ED workflow, it can lead to a more rapid diagnosis, enabling appropriate treatments and avoiding unnecessary delays and invasive tests in patients who do not have coronary artery disease.

"The COR Analyzer is expected to assist the ED staff in reading Coronary CTA studies 24/7. Prioritizing patients with CAD, identifying and characterizing pathologies will save time and improve workflow in the ED as well as the radiology and cardiology departments," commented Shai Levanon, Rcadia CEO.

Coronary CTA studies are sent from the CT scanner to the COR Analyzer and analyzed without human intervention. The COR Analyzer is highly reliable in ruling out coronary artery disease. In analyzing over 350 CTA studies, generated by all four CT manufacturers, the Rcadia COR Analyzer successfully identified coronary artery disease and had a high NPV of over 97%.

"As a result of the COR Analyzer high negative predictive value we are currently finalizing testing of the product and strongly hope to start using it to triage cases that need to be read, alerting the reader which patients are most likely to have coronary arterial disease. Since COR Analyzer automatically marks pathologies; this in turn will make reading cases significantly faster even for the experienced radiologists." added Nathan Peled, MD, Head Department of Radiology at the Lady Davis Carmel Medical Center in Haifa.


'/>"/>
SOURCE Rcadia Medical Imaging, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dade Behrings (hsCRP) Tests and BNTM Series Analyzers
2. Analyzers Offer Point-of-Care Lipid Panels
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Urinalysis Analyzers: Large Capabilities in Every Size Device
6. New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
7. PromegaExpress Expands Easy Access to Products with New Cabinet
8. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... the only authorized OSHA Training Institute Education Center headquartered in Northern California, has ... workers from extreme heat at their worksites. Employers with workers exposed to ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):